#Denmark #Copenhagen #Adcendo #ADCE-D01 #soft tissue sarcoma

Adcendo Initiates Phase I/II Clinical Trial of ADCE-D01

Adcendo ApS, a pioneering clinical-stage biotech company, has taken a monumental step in the fight against soft tissue sarcoma (STS) by dosing the first patient in its Phase I/II ADCElerate1 clinical trial. This trial is significant as it evaluates ADCE-D01, an innovative antibody-drug conjugate (ADC) specifically designed to target uPARAP, an endocytic receptor that is markedly overexpressed in various mesenchymal cancers, including multiple subtypes of STS.

The initial dose was administered at the renowned Memorial Sloan Kettering Cancer Center in New York, a pivotal site in cancer treatment and research. The ADCElerate1 trial, identified by NCT06797999, is structured as a multicenter, open-label study. The primary goal is to assess the safety and tolerability of ADCE-D01 as a monotherapy for patients with metastatic and/or unresectable STS, while secondary objectives focus on pharmacokinetics and preliminary efficacy results.

Dr. Lone Ottesen, Adcendo’s Chief Medical Officer, reflected on this milestone, emphasizing the potential impact of ADCE-D01 on patients struggling with advanced STS. She noted, "This dosing event represents not only a key achievement for Adcendo but also for the entire uPARAP program. We are eager to witness how ADCE-D01 may benefit patients facing the challenges of advanced STS. The target receptor, uPARAP, is particularly interesting due to its significant presence in multiple STS subtypes and its limited expression in healthy tissues."

The transition into the European market is also underway, with the European clinical trial application recently receiving approval, allowing the study to extend its reach across both the U.S. and Europe.

Professor Robert Maki, MD, PhD, who serves as a sarcoma oncologist at Memorial Sloan Kettering, acknowledged the collaboration with Adcendo on this project, stating, "We are thrilled to partner with Adcendo in the development of ADCE-D01, as it provides hope to many STS patients who currently have scant treatment options. The influence of ADCs in cancer therapies has been profound, and we are enthusiastic about introducing this pioneering treatment to our patients."

ADCE-D01 epitomizes an advanced method of addressing cancer treatment, targeting the uPARAP receptor, which plays a crucial role in collagen metabolism. While exhibiting low levels of expression in healthy tissues, uPARAP is found to be significantly upregulated in various mesenchymal cancers, such as STS and bone sarcoma, making it an optimal target for ADC development. As it advances through phase I/II clinical trials, ADCE-D01 underpins Adcendo’s broader mission to forge a pathway for innovative cancer therapies that address unmet medical needs.

About Adcendo

Adcendo, headquartered in Copenhagen, Denmark, and with operations in Boston, Massachusetts, is at the forefront of developing a new line of ADCs aimed at treating cancers with significant unmet therapeutic needs. Their team, made up of seasoned industry professionals, combines state-of-the-art targets with meticulously designed linker-payload combinations to propel the next generation of cancer treatments. For more extensive details, follow their journey on Adcendo's website or LinkedIn.

As the clinical trials evolve and further data emerge, the medical community watches closely—anticipating the hopeful outcomes that this groundbreaking ADC could bring to those afflicted by advanced soft tissue sarcoma.